Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T.
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN.
Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625.
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, Gangat N.
Am J Hematol. 2021 Jun 1;96(6):E182-E184. doi: 10.1002/ajh.26137. Epub 2021 Mar 11.
Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?
Spivak JL.
Leukemia. 2021 Jul;35(7):1890-1893. doi: 10.1038/s41375-021-01254-w. Epub 2021 Apr 28.
Asymptomatic Essential Thrombocytosis Presenting with Extrahepatic Portal Vein Thrombosis: A Case Report.
Yakami Y, Yagyu T, Bando T, Hanada M.
Am J Case Rep. 2023 Sep 28;24:e938547. doi: 10.12659/AJCR.938547.
Essential thrombocytosis attributed to JAK2-T875N germline mutation.
Yoshimitsu M, Hachiman M, Uchida Y, Arima N, Arai A, Kamada Y, Shide K, Ito M, Shimoda K, Ishitsuka K.
Int J Hematol. 2019 Nov;110(5):584-590. doi: 10.1007/s12185-019-02725-8. Epub 2019 Aug 19.
[Thrombocytosis and essential thrombocythemia in childhood].
Mialou V, Kagialis-Girard S, Galambrun C, Pondarré C, Kebaili K, Ffrench M, Pagès MP, Bertrand Y.
Arch Pediatr. 2005 Aug;12(8):1249-54. doi: 10.1016/j.arcped.2005.04.072.
Thrombocytosis and thrombocythemia.
Schafer AI.
Blood Rev. 2001 Dec;15(4):159-66. doi: 10.1054/blre.2001.0162.
Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G.
Ann Hematol. 2009 Jan;88(1):1-10. doi: 10.1007/s00277-008-0531-7. Epub 2008 Jul 16.
Thrombocytosis.
Schafer AI.
N Engl J Med. 2004 Mar 18;350(12):1211-9. doi: 10.1056/NEJMra035363.
